Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prateek Mendiratta

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Androgen Deprivation FortifiedPrateek Mendiratta, Jorge Garcia
Annals of Translational Medicine|August 3, 2018
Emerging biomarkers and targeted therapies in urothelial carcinomaPrateek Mendiratta, Petros Grivas
Molecular Diagnosis & Therapy|December 15, 2007
Genomic signatures associated with the development, progression, and outcome of prostate cancerPrateek Mendiratta, Phillip G Febbo
Reviews in Urology|March 28, 2007
Current standard and investigational approaches to the management of hormone-refractory prostate cancerPrateek Mendiratta, Andrew J Armstrong, Daniel J George
Urology|December 6, 2017
Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and RadiationPrateek Mendiratta, Brian I Rini, Rahul D Tendulkar
Urologic Oncology|September 12, 2017
Emerging immunotherapy in advanced renal cell carcinomaPrateek Mendiratta, Brian I Rini, Moshe C Ornstein
Investigational New Drugs|September 8, 2018
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II studyPedro C Barata, Matthew Cooney, Prateek Mendiratta, et al.
Investigational New Drugs|November 8, 2018
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancerPedro C Barata, Matthew Cooney, Prateek Mendiratta, et al.
Therapeutic Advances in Urology|May 23, 2024
Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancerChaim Domb, Jorge A Garcia, Pedro C Barata, et al.
Journal of Translational Medicine|July 6, 2018
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanomaJanet Retseck, Alexis Nasr, Yan Lin, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
International Journal of Radiation Oncology, Biology, Physics|May 4, 2018
Androgen Deprivation FortifiedPrateek Mendiratta, Jorge Garcia
Annals of Translational Medicine|August 3, 2018
Emerging biomarkers and targeted therapies in urothelial carcinomaPrateek Mendiratta, Petros Grivas
Molecular Diagnosis & Therapy|December 15, 2007
Genomic signatures associated with the development, progression, and outcome of prostate cancerPrateek Mendiratta, Phillip G Febbo
Reviews in Urology|March 28, 2007
Current standard and investigational approaches to the management of hormone-refractory prostate cancerPrateek Mendiratta, Andrew J Armstrong, Daniel J George
Urology|December 6, 2017
Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and RadiationPrateek Mendiratta, Brian I Rini, Rahul D Tendulkar
Urologic Oncology|September 12, 2017
Emerging immunotherapy in advanced renal cell carcinomaPrateek Mendiratta, Brian I Rini, Moshe C Ornstein
Investigational New Drugs|September 8, 2018
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II studyPedro C Barata, Matthew Cooney, Prateek Mendiratta, et al.
Investigational New Drugs|November 8, 2018
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancerPedro C Barata, Matthew Cooney, Prateek Mendiratta, et al.
Therapeutic Advances in Urology|May 23, 2024
Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancerChaim Domb, Jorge A Garcia, Pedro C Barata, et al.
Journal of Translational Medicine|July 6, 2018
Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanomaJanet Retseck, Alexis Nasr, Yan Lin, et al.
Pageof 4